Review ArticlesCardiac Myxoma: Review and Update of Contemporary Immunohistochemical Markers and Molecular PathologyVelez Torres, Jaylou M. MD*; Martinez Duarte, Ernesto MD†; Diaz-Perez, Julio A. MD*; Rosenberg, Andrew E. MD*Author Information *Department of Pathology, University of Miami Miller School of Medicine, Miami, FL †Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE The authors have no funding or conflicts of interest to disclose. All figures can be viewed online in color at www.anatomicpathology.com. Reprints: Jaylou M. Velez Torres, MD, Department of Pathology, University of Miami Hospital Miller School of Medicine, 1400 NW 12th Avenue, Room 4078, Miami, FL 33136 (e-mail: firstname.lastname@example.org). Advances In Anatomic Pathology: November 2020 - Volume 27 - Issue 6 - p 380-384 doi: 10.1097/PAP.0000000000000275 Buy Metrics Abstract Cardiac myxoma is an uncommon benign mesenchymal neoplasm of the heart. It usually arises in the left atrium, near the valve of the fossa ovalis, and most frequently affects adults in the third through the sixth decades of life. It is hypothesized to arise from subendothelial vasoformative reserve cells or primitive cells that differentiate along the lines of the endothelium, but this remains speculative. Microscopically, the neoplastic cells are arranged individually, and nests, and are oriented in single or multiple layers around vascular channels. The neoplastic cells are immunoreactive for vimentin, calretinin, S100, nonspecific enolase, factor VIII, CD31, and CD34. The tumor can have diverse clinical presentations depending on its location and extent of disease and is predisposed to embolization. The current treatment is prompt surgical excision. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.